United States Health

HUTCHMED (NASDAQ:HCM) initiated a global Phase Ia clinical trial of HMPL-A830 in patients with advanced solid tumors, with the first patient receiving a dose in China on September 24, 2026.

QIAGEN (NYSE:QGEN) received U.S. Food and Drug Administration clearance for its QIAstat-Dx BCID GN Plus AMR Panel, expanding access to its bloodstream infection testing portfolio for U.S. laboratories.

Tandem Diabetes Care (NASDAQ:TNDM) announced that Tandem Mobi, its automated insulin delivery system, is now available in 12 countries outside the United States, with the company accepting orders and shipping to eligible customers.

Nektar Therapeutics (NASDAQ:NKTR) received a jury verdict awarding the company $90 million in damages after a court found Eli Lilly (NYSE:LLY) breached the implied covenant of good faith and fair dealing related to a prior rezpegaldesleukin license agreement.

Firefly Neuroscience (NASDAQ:AIFF) and NeuroSigma announced a partnership to introduce NeuroSigma’s Monarch eTNS System to clinicians using Firefly’s Evoke brain-function assessment platform.

Johnson & Johnson (NYSE:JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study evaluating adults with active psoriatic arthritis and MRI-confirmed axial inflammation.

Legend Biotech (NASDAQ:LEGN) reported five-year results from the Phase 2 CARTITUDE-2 Cohort A study showing that 10 of 20 patients treated with a single CARVYKTI infusion remained alive and progression-free without further anti-myeloma treatment.

Ocugen (NASDAQ:OCGN) announced that OCU400 received provisional approval and priority designation in The Bahamas for the treatment of retinitis pigmentosa, an inherited eye disorder.

C4 Therapeutics (NASDAQ:CCCC) presented new biomarker data from two Phase 1 multiple myeloma combination trials evaluating cemsidomide, including studies with dexamethasone and elranatamab.

Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.

AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.

Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.